You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 1, 2026

Drug Price Trends for DESMOPRESSIN


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for DESMOPRESSIN

Average Pharmacy Cost for DESMOPRESSIN

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
DESMOPRESSIN 10 MCG/0.1 ML SPR 60505-0815-00 11.34685 ML 2026-03-18
DESMOPRESSIN ACETATE 0.2 MG TB 69918-0201-01 0.36035 EACH 2026-03-18
DESMOPRESSIN 40 MCG/10 ML VIAL 69918-0901-11 19.17540 ML 2026-03-18
DESMOPRESSIN 40 MCG/10 ML VIAL 25021-0461-10 19.17540 ML 2026-03-18
DESMOPRESSIN 40 MCG/10 ML VIAL 39822-6250-01 19.17540 ML 2026-03-18
DESMOPRESSIN 40 MCG/10 ML VIAL 65219-0295-10 19.17540 ML 2026-03-18
DESMOPRESSIN 40 MCG/10 ML VIAL 69918-0901-10 19.17540 ML 2026-03-18
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for DESMOPRESSIN

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type
DESMOPRESSIN 0.1MG TAB Golden State Medical Supply, Inc. 60505-0257-01 100 16.98 0.16980 EACH 2024-01-01 - 2028-06-14 FSS
DESMOPRESSIN 0.2MG TAB Golden State Medical Supply, Inc. 60505-0258-01 100 19.15 0.19150 EACH 2024-01-01 - 2028-06-14 FSS
DESMOPRESSIN ACETATE 0.1MG/ML SOLN,NASAL SPRA Golden State Medical Supply, Inc. 60505-0815-00 5ML 19.10 3.82000 ML 2023-06-15 - 2028-06-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Unit >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market overview and price projections for DESMOPRESSIN

Last updated: February 12, 2026

Desmopressin, a synthetic analog of vasopressin, is used primarily for diabetes insipidus, bedwetting, and bleeding disorders such as von Willebrand disease and hemophilia A. The drug's market dynamics are influenced by its therapeutic efficacy, patents, generic development, regulatory status, and emerging competitor therapies.


Current Market Status

  • The global desmopressin market was valued at approximately $1.2 billion in 2022.
  • Growth rate (CAGR): 4-6% over the next five years, driven by expanding indications and aging populations.
  • Leading markets: United States, European Union, Japan.
  • Major manufacturers: Ferring Pharmaceuticals, Pfizer, Sandoz (Novartis), and Mylan (part of Viatris).

Market Segments

Segment Share (2022) Growth Drivers
Oral desmopressin 50% Ease of administration, compliance
Intranasal formulations 30% Still popular but declining due to inconvenience
Injectable forms 20% Used in hospital settings, emergency situations

Growth is mainly driven by increased diagnosis of conditions like diabetes insipidus and bleeding disorders, plus expanding use in pediatric and adult populations.


Patent and Regulatory Influence

  • Many formulations, especially injectable and oral tablets, are off-patent, opening markets for generics.
  • Patent expirations observed between 2013 and 2020 in key markets, leading to increased generic competition.
  • Regulatory approvals for new formulations or delivery methods could induce price shifts, but are currently limited.

Price Projections

Formulation 2022 Avg. Price (per unit) Projected 2027 Price (per unit) Notes
Oral tablets (5-10 mcg) ~$5 per strip $3-6 per strip Increased generics reduce price
Intranasal spray ~$15 per spray $10-20 per spray Slight price stability; affected by competition
Injectable (vials) ~$20-$30 per vial $15-$25 per vial Price compression from competition and biosimilar entry

Note: Prices vary by region, dosage strength, and formulation. US and European markets show similar trends but differ in pricing levels due to reimbursement policies.


Competitive and Pricing Trends

  • Generics dominate the market, causing price erosion.
  • Biosimilars are in early development phases; upcoming entries could further depress prices over the next decade.
  • The rise of alternative therapies (e.g., desmopressin analogs, other hemostatic agents) could impact market share.

Key Drivers and Risks

  • Increase in diagnosed indications: Expanding use in enuresis, bleeding, and sleep disorders.
  • Patent cliffs: Generic entry lowers prices.
  • Regulatory challenges: New formulations or delivery methods may face approval hurdles.
  • Pricing pressures: Payers seek low-cost options, influencing Medicare/Medicaid reimbursement.

Conclusion

The desmopressin market is mature, with steady growth driven by indications expansion and aging demographics. Price erosion due to generics is expected to continue, with prices decreasing by approximately 20-40% over five years for key formulations. The clinics' preference for oral over nasal or injectable forms influences market dynamics.


Key Takeaways

  • The global market size is approximately $1.2 billion, growing at 4-6% annually.
  • Oral tablets and intranasal sprays are the primary formulations, with prices declining due to generics.
  • Price drops of 20-40% are projected for key formulations through 2027.
  • Regulatory and patent developments will shape the landscape, with biosimilars emerging.
  • Competition and payer policies pressure prices downward, impacting margins.

FAQs

  1. What are the main therapeutic uses of desmopressin? It treats diabetes insipidus, enuresis (bedwetting), and bleeding disorders such as von Willebrand disease and hemophilia A.

  2. How does patent protection influence desmopressin prices? Patent expirations, mainly between 2013 and 2020, led to increased generic competition, reducing prices significantly.

  3. What are the key drivers for market growth? Improved diagnosis rates, expanded indications, and aging populations.

  4. What potential threats could disrupt the market? Development of biosimilars, new therapeutic alternatives, and regulatory hurdles for new formulations.

  5. How do regional differences affect pricing? US and European markets display similar trends; however, reimbursement policies cause variations in unit prices.


Citations

[1] MarketsandMarkets, "Desmopressin Market by Application and Region," 2022.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.